Sun Pharma Shares Rise After FDA Approval For Cancer Drug
The firm, which is headquartered in Mumbai released a statement saying that its subsidiary has received the green light for US Food and Drug Administration for its Doxorubicin HCI Liposome Injection.
“This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC,” the company said.
Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer, which has progressed or recurred after platinum-based chemotherapy.
Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 percent from their previous close.
Featured Articles
NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system
Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment
A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency